The Role of GIP in Postprandial Splanchnic Blood Flow Distribution and Metabolism in Patients With Type 2 Diabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project will describe the mechanisms of action and the relative contributions of GIP to changes in gastrointestinal blood flow induced by oral glucose and endogenous GIP with the use of a receptor antagonists GIP(3-30)NH2 in patients with type 2 diabetes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Role of GIP and GLP-2 in Postprandial Splanchnic Blood Flow Distribution and Metabolism

NCT05391581

Blood Flow

COMPLETED NA

GIP Receptor Antagonist Studies in Humans

NCT02747472

Glucose Metabolism

COMPLETED NA

The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes

NCT00732602

Diabetes Mellitus

COMPLETED NA

Effect of GIP After a Meal in Patients With Type 2 Diabetes

NCT03702660

Type2 Diabetes

COMPLETED NA

GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia

NCT00716170

Type 2 Diabetes Mellitus

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Each participant will attend four independent randomised experimental days in the MRI-scanner with intravenous infusion (hormone/placebo) and oral ingestion (glucose/water): An intravenous infusion of saline or GIP(3-30)NH2 starts at time point -20 minutes.The infusions are combined with an oral glucose tolerance test (75 gram of glucose dissolved in 250 ml water ingested orally) at time point 0 minutes on two of the experimental days (with and without GIP(3-30)NH2).

MRI measurements are repeatedly performed and blood samples are drawn to be analysed for endocrine responses from the intestines, pancreas, and bones.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Blood Flow

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Single blind, placebo controlled, randomized, crossover study

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Saline and oral water (SAL-WAT)

Saline infusion, oral water ingestion

Group Type PLACEBO_COMPARATOR

Saline / placebo

Intervention Type OTHER

NaCl (9 mg/ml)

Saline infusion and oral glucose ingestion (SAL-GLU)

Saline infusion, oral glucose ingestion

Group Type ACTIVE_COMPARATOR

Saline / placebo

Intervention Type OTHER

NaCl (9 mg/ml)

GIP(3-30)NH2 infusion and oral water ingestion (GIA-WAT)

GIPR antagonist infusion, oral water ingestion

Group Type EXPERIMENTAL

GIPR antagonist / study tool

Intervention Type OTHER

GIP(3-30)NH2

GIP(3-30)NH2 infusion and oral glucose ingestion (GIA-GLU)

GIPR antagonist infusion, oral glucose ingestion

Group Type EXPERIMENTAL

GIPR antagonist / study tool

Intervention Type OTHER

GIP(3-30)NH2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Saline / placebo

NaCl (9 mg/ml)

Intervention Type OTHER

GIPR antagonist / study tool

GIP(3-30)NH2

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 2 diabetes
* BMI 20-35 kg/m\^2
* Age 20-80

Exclusion Criteria

* Not MRI-compatible implants
* Claustrophobia
* Abnormal kidney or liver function
* Anemia
* Planned weight loss or change in diet
* Hypertension
* Other conditions that could be expected to affect the primary or secondary outcomes

Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No